Additionally, FGF-21 levels of ≥285.6 ng/mL yielded 64% sensitivity and 84% specificity for distinguishing individuals with metabolic syndrome from those who do not meet the criteria, while levels of ≥275.7 ng/mL provided a sensitivity of 68% and specificity of 65% for identifying subjects with dyslipidemia. This evidence concerns the gene FGF21 and metabolic syndrome.